


MOVING TOWARDS NORMALISED HAEMOSTASIS IN THE REAL WORLD

Wednesday 4 February 2026
14:30–15:30, EAHAD 2026
Room Liffey B

ALTUVOCT 
efanesoctocog alfa (recombinant coagulation factor VIII,
Fc-Von Willebrand Factor-XTEN Fusion Protein)

Maria Elisa Mancuso (Chair), Italy
Targeting Normalised Haemostasis
in Haemophilia A With ALTUVOCT®

Yesim Dargaud, France
The Role of FVIII Replacement in
the Evolving Treatment Landscape

Johannes Oldenburg, Germany

Mary Mathias, United Kingdom
Real-World Data: ALTUVOCT® in Practice

Please connect with your local Sobi™ representative for any questions
Please click on this link for more information: [Altuvoc | European Medicines Agency \(EMA\)](#)
This is a promotional symposium intended for healthcare professionals, produced and paid for by Sobi™
Sobi™ is a trademark of Swedish Orphan Biovitrum AB (publ)
©2025 Swedish Orphan Biovitrum AB (publ) – all rights reserved
Swedish Orphan Biovitrum AB (publ). SE-112 76 Stockholm, Sweden. www.sobi.com
PP-30662. Date of preparation: November 2025



▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any Adverse Event (AE) including any suspected adverse drug reactions (ADRs) to Swedish Orphan Biovitrum AB by email: drugsafety@sobi.com